Oligomerix, Inc.

Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy dementia to Alzheimer’s disease. Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau selfassociation that are potentially easy to administer and cost-effective. Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative orcomplement the newly emerging high-cost therapeutic options such as monoclonal antibody products.